WeVote
Log In

Bill

Bill

HB 2558

insurance; cancer; chemotherapy; scalp cooling

57th Legislature - Second Regular Session Introduced by Anna Abeytia and 10 co-sponsors

Arizona would require health insurers to cover scalp cooling technology and services for chemotherapy patients to prevent hair loss, increasing insurance costs while improving cancer treatment quality of life.

House First Reading.
0
WeVote Research Nonpartisan
Bill Summary · HB 2558

Legislative bill overview

HB 2558 would require health insurance plans in Arizona to cover scalp cooling technology during chemotherapy treatment. Scalp cooling systems work by reducing temperature at the scalp to minimize hair loss (alopecia) that commonly occurs as a side effect of cancer treatment. The bill mandates insurance coverage for both the device and related medical services.

Why is this important

Hair loss from chemotherapy can have significant psychological and quality-of-life impacts on cancer patients, affecting self-image and emotional wellbeing during already-difficult treatment. While scalp cooling technology exists and can be effective, it remains expensive and often unavailable to patients without insurance coverage, creating access disparities. This legislation would remove financial barriers to a treatment that many patients seek but cannot afford.

Potential points of contention

  • Cost and insurance premiums: Mandating coverage for scalp cooling devices and services will increase insurance costs, potentially raising premiums for all policyholders to cover a benefit used by a subset of cancer patients
  • Medical necessity debate: Some stakeholders may argue scalp cooling is cosmetic rather than medically necessary, since hair loss doesn't affect survival outcomes, while others counter that quality of life during cancer treatment is legitimate medical concern
  • Scope and coverage details: The bill's specific language on what devices qualify, which medical services are covered, frequency of treatments, and patient eligibility requirements remains unclear from this summary and could generate disagreement during committee review

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.